Ildong Pharmaceutical Expands Dyslipidemia Treatment 'Droptop' into Four Additional Southeast Asian Countries

Expansion of Local Supply Agreement with Indonesia's Kalbe Group

On September 11, Ildong Pharmaceutical announced that it will expand the scope of its existing agreement with its Indonesian partner, Kalbe Farma, regarding the supply of the dyslipidemia treatment "Droptop," and will also seek to enter additional Southeast Asian markets in the region.

Ildong Pharmaceutical Headquarters, Seocho-gu, Seoul. Ildong Pharmaceutical

Droptop is a combination drug for the treatment of dyslipidemia, containing rosuvastatin, a statin that inhibits cholesterol synthesis in the body, and ezetimibe, which blocks cholesterol absorption.

In 2020, Ildong Pharmaceutical signed a partnership agreement with Kalbe Farma, Indonesia's leading pharmaceutical company, for the supply of Droptop. Following regulatory approval and product launch procedures, the company has been exporting this product since 2023.

Droptop is marketed locally under the brand name "Rozet" and has achieved an average annual growth rate of 125% over the past three years, securing the top market share in Indonesia's combination drug segment for dyslipidemia.

Recently, Ildong Pharmaceutical signed an additional supply agreement for Droptop with Kalbe International, the export and distribution subsidiary of Kalbe Farma, covering four Southeast Asian countries: the Philippines, Cambodia, Myanmar, and Sri Lanka.

Kalbe International has local subsidiaries in major Southeast Asian countries and boasts a robust distribution network based on more than 18,000 distribution channels and logistics networks. The company has steadily expanded its market influence in the pharmaceutical sector, leveraging localized marketing and joint venture strategies.

Under the new agreement, Ildong Pharmaceutical will receive an upfront payment and secure the right to receive milestone payments based on future Droptop supplies. The company plans to accelerate all necessary procedures for launching Droptop in the contracted countries, including pursuing regulatory approvals, in cooperation with Kalbe International.

An Ildong Pharmaceutical representative stated, "The success we achieved in Indonesia has enabled us to strengthen our partnership with the Kalbe Group. We plan to expand Droptop's presence in the four newly contracted countries and other major Southeast Asian markets, while also seeking to broaden collaboration on other products in our portfolio."

This content was produced with the assistance of AI translation services.